Dr Luke on the Background of the KEYNOTE-716 Trial in High-Risk Melanoma
August 18th 2023
Jason Luke, MD, FACP, discusses the background of the phase 3 KEYNOTE-716 trial of pembrolizumab vs placebo as adjuvant therapy in patients with stage IIB or IIC melanoma, highlighting previous data from the trial that led to the 36-month follow-up report.